dc.contributor.author
Ruggeri, Annalisa
dc.contributor.author
Battipaglia, Giorgia
dc.contributor.author
Labopin, Myriam
dc.contributor.author
Ehninger, Gerhard
dc.contributor.author
Beelen, Dietrich
dc.contributor.author
Tischer, Johanna
dc.contributor.author
Ganser, Arnold
dc.contributor.author
Schwerdtfeger, Rainer
dc.contributor.author
Glass, Bertram
dc.contributor.author
Finke, Jurgen
dc.contributor.author
Michallet, Mauricette
dc.contributor.author
Stelljes, Matthias
dc.contributor.author
Jindra, Pavel
dc.contributor.author
Arnold, Renate
dc.contributor.author
Kröger, Nicolaus
dc.contributor.author
Mohty, Mohamad
dc.contributor.author
Nagler, Arnon
dc.date.accessioned
2018-06-08T03:22:12Z
dc.date.available
2016-10-19T10:48:35.083Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/15028
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-19216
dc.description.abstract
Background Allogeneic stem cell transplantation is the only curative option
for patients with acute myeloid leukemia (AML) experiencing relapse. Either
matched sibling donor (MSD) or unrelated donor (UD) is indicated. Methods We
analyzed 1554 adults with AML transplanted from MSD (n = 961) or UD (n = 593,
HLA-matched 10/10, n = 481; 9/10, n = 112). Compared to MSD, UD recipients
were older (49 vs 52 years, p = 0.001), transplanted more recently (2009 vs
2006, p = 0.001), and with a longer interval to transplant (10 vs 9 months, p
= 0.001). Conditioning regimen was more frequently myeloablative for patients
transplanted with a MSD (61 vs 46 %, p = 0.001). Median follow-up was 28
(range 3–157) months. Results Cumulative incidence (CI) of neutrophil
engraftment (p = 0.07), grades II–IV acute GVHD (p = 0.11), chronic GVHD (p =
0.9), and non-relapse mortality (NRM, p = 0.24) was not different according to
the type of donor. At 2 years, CI of relapse (relapse incidence (RI)) was 57
vs 49 % (p = 0.001). Leukemia-free survival (LFS) at 2 years was 21 vs 26 % (p
= 0.001), and overall survival (OS) was 26 vs 33 % (p = 0.004) for MSD vs UD,
respectively. Chronic GVHD as time-dependent variable was associated with
lower RI (HR 0.78, p = 0.05), higher NRM (HR 1.71, p = 0.001), and higher OS
(HR 0.69, p = 0.001). According to HLA match, RI was 57 vs 50 vs 45 %, (p =
0.001) NRM was 23 vs 23 vs 29 % (p = 0.26), and LFS at 2 years was 21 vs 27 vs
25 % (p = 0.003) for MSD, 10/10, and 9/10 UD, respectively. In multivariate
analysis adjusted for differences between the two groups, UD was associated
with lower RI (HR 0.76, p = 0.001) and higher LFS (HR 0.83, p = 0.001)
compared to MSD. Interval between diagnosis and transplant was the other
factor associated with better outcomes (RI (HR 0.62, p < 0.001) and LFS (HR
0.67, p < 0.001)). Conclusions Transplantation using UD was associated with
better LFS and lower RI compared to MSD for high-risk patients with AML
transplanted in first relapse.
en
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
Acute myeloid leukemia
dc.subject
Matched sibling donor
dc.subject
Unrelated donor
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Unrelated donor versus matched sibling donor in adults with acute myeloid
leukemia in first relapse
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
Journal of Hematology & Oncology. - 9 (2016), Artikel Nr. 89
dc.title.subtitle
an ALWP-EBMT study
dcterms.bibliographicCitation.doi
10.1186/s13045-016-0321-y
dcterms.bibliographicCitation.url
http://jhoonline.biomedcentral.com/articles/10.1186/s13045-016-0321-y
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000025580
refubium.note.author
Der Artikel wurde in einer reinen Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000007240
dcterms.accessRights.openaire
open access